Gain Therapeutics, founded with a mission to address protein misfolding diseases, is a preclinical biotechnology company. The firm focuses on developing allosteric small molecule therapies using its proprietary drug discovery platform, MAGELLAN™. Their lead drug candidate, GT-, is designed for treating GBA-Parkinson’s disease and other neurodegenerative conditions and is currently undergoing Phase I clinical trials. Gain Therapeutics aims to revolutionize treatment options for patients suffering from these debilitating diseases.
Notable figures associated with Gain Therapeutics include key scientific advisors and experienced industry professionals who contribute to its innovative approach. The company has attracted significant investment from reputable biotech investors, underscoring confidence in its potential. Gain Therapeutics' achievements in advancing its lead candidate to clinical trials mark a significant milestone, positioning the company as a promising player in the biotech landscape focused on neurodegenerative diseases.
